Magnetar Financial LLC Has $26.13 Million Stock Position in LivaNova PLC (NASDAQ:LIVN)

Magnetar Financial LLC cut its holdings in LivaNova PLC (NASDAQ:LIVN - Free Report) by 22.7% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 564,197 shares of the company's stock after selling 165,916 shares during the quarter. Magnetar Financial LLC owned approximately 1.04% of LivaNova worth $26,128,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Xponance Inc. boosted its stake in shares of LivaNova by 6.1% in the 4th quarter. Xponance Inc. now owns 7,762 shares of the company's stock valued at $359,000 after purchasing an additional 445 shares in the last quarter. Cibc World Markets Corp acquired a new stake in LivaNova in the fourth quarter valued at approximately $236,000. Vestcor Inc bought a new stake in shares of LivaNova during the fourth quarter worth $204,000. Swiss National Bank lifted its stake in shares of LivaNova by 0.7% in the 4th quarter. Swiss National Bank now owns 106,819 shares of the company's stock valued at $4,947,000 after acquiring an additional 700 shares during the last quarter. Finally, Ruffer LLP acquired a new stake in shares of LivaNova during the 4th quarter valued at $7,982,000. Institutional investors own 97.64% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Wolfe Research downgraded LivaNova from an "outperform" rating to a "peer perform" rating in a research report on Wednesday, February 26th. Needham & Company LLC reissued a "buy" rating and set a $64.00 target price on shares of LivaNova in a report on Monday, March 17th. Mizuho dropped their price target on shares of LivaNova from $70.00 to $60.00 and set an "outperform" rating for the company in a research note on Wednesday, February 26th. The Goldman Sachs Group reduced their price objective on shares of LivaNova from $64.00 to $55.00 and set a "buy" rating on the stock in a research note on Monday, March 3rd. Finally, StockNews.com lowered LivaNova from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $61.17.

Remove Ads

LivaNova Trading Up 2.3 %

Shares of LIVN stock traded up $0.89 during mid-day trading on Monday, hitting $40.37. The company's stock had a trading volume of 595,226 shares, compared to its average volume of 594,564. The company has a market cap of $2.19 billion, a PE ratio of 96.12 and a beta of 1.10. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. The company's fifty day simple moving average is $45.31 and its 200-day simple moving average is $48.74. LivaNova PLC has a 52 week low of $36.85 and a 52 week high of $64.48.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.